Ultra-low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myeloma.
molecular cytogenetics
multiple myeloma
prognostic factor
ultra-low depth sequencing
Journal
Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
28
12
2019
revised:
22
03
2020
accepted:
01
04
2020
pubmed:
8
4
2020
medline:
7
7
2021
entrez:
8
4
2020
Statut:
ppublish
Résumé
Cytogenetic abnormalities are powerful prognostic factors in multiple myeloma (MM) and are routinely analyzed by FISH on bone marrow (BM) plasma cells (PC). Although considered the gold standard, FISH experiments can be laborious and expensive. Therefore, array-CGH (aCGH) has been introduced as an alternative approach for detecting copy number aberrations (CNA), reducing the number of FISH experiments per case and yielding genome-wide information. Currently, next generation sequencing (NGS) technologies offer new perspectives for the diagnostic workup of malignant disorders. In this study, we examined ultra-low depth whole genome sequencing (LDS) as a valid alternative for aCGH for the detection of CNA in BM PC in MM. To this end, BM aspirates obtained in a diagnostic setting from 20 MM cases were analyzed. CD138+ cell-sorted samples were subjected to FISH analysis. DNA was extracted for subsequent aCGH and LDS analysis. CNA were detected by aCGH and LDS in all but one case. Importantly, all CNA identified by parallel first generation aCGH analysis were also detected by LDS, along with six additional CNA in five cases. One of these additional aberrations was in a region of prognostic importance in MM and was confirmed using FISH. However, risk stratification in these particular cases was unaffected. Thus, a perfectly concordant prognostication between array-CGH and LDS was observed. This validates LDS as a novel and cost-efficient tool for the detection of CNA in MM.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
465-471Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. https://doi.org/10.1016/S1470-2045(14)70442-5.
Sonneveld P, Lonial S, Usmani S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood. 2017;127(24):2955-2963. https://doi.org/10.1182/blood-2016-01-631200.BLOOD.
Caers J, Garderet L, Kortüm KM, et al. European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018;103(11):1772-1784. https://doi.org/10.3324/haematol.2018.189159.
Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113. https://doi.org/10.1038/nrclinonc.2016.122.
Fonseca R, Bergsagel PL, Drach J, et al. International myeloma working group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-2221. https://doi.org/10.1038/leu.2009.174.
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2017.
Nooka AK, Lonial S. New targets and new agents in high-risk multiple myeloma. Am Soc Clin Oncol Educ B. 2016;36:e431-e441. https://doi.org/10.14694/edbk_159516.
Dong Z, Zhang J, Hu P, et al. Low-pass whole-genome sequencing in clinical cytogenetics: a validated approach. Genet Med. 2016;18(9):940-948. https://doi.org/10.1038/gim.2015.199.
Koh CM. Preparation of Cells for Microscopy Using Cytospin. Vol 533. 1st ed. Elsevier Inc.; 2013. https://doi.org/10.1016/B978-0-12-420067-8.00016-7.
Wuilleme S, Robillard N, Lodé L, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2005;19(2):275-278. https://doi.org/10.1038/sj.leu.2403586.
Ross FM, Avet-Loiseau H, Ameye G, et al. Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97(8):1272-1277. https://doi.org/10.3324/haematol.2011.056176.
Li Y, Wang X, Zheng H, et al. Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles. PLoS One. 2013;8(3):2-12. https://doi.org/10.1371/journal.pone.0058809.
Scheinin I, Sie D, Bengtsson H, et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 2014;24(12):2022-2032. https://doi.org/10.1101/gr.175141.114.
Simons A, Sikkema-Raddatz B, de Leeuw N, Konrad NC, Hastings RJ, Schoumans J. Genome-wide arrays in routine diagnostics of hematological malignancies. Hum Mutat. 2012;33(6):941-948. https://doi.org/10.1002/humu.22057.
Schoumans J, Suela J, Hastings R, et al. Guidelines for genomic array analysis in acquired haematological neoplastic disorders. Genes Chromosomes Cancer. 2016;55:480-491. https://doi.org/10.1002/gcc.
Vandenberghe P, Wlodarska I, Tousseyn T, et al. Non-invasive detection of genomic imbalances in Hodgkin/reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol. 2015;2(2):55-65.
Elnenaei MO, Knopf P, Cutler SD, et al. Low-depth sequencing for copy number abnormalities in multiple myeloma supersedes fluorescent in situ hybridization in scope and resolution. Clin Genet. 2019;96(2):163-168. https://doi.org/10.1111/cge.13561.
Chin SF, Santonja A, Grzelak M, et al. Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers. Exp Mol Pathol. 2018;104(3):161-169. https://doi.org/10.1016/j.yexmp.2018.03.006.
Smadbeck JB, Johnson SH, Smoley SA, et al. Copy number variant analysis using genome-wide mate-pair sequencing. Genes Chromosomes Cancer. 2018;57(9):459-470. https://doi.org/10.1002/gcc.5.
Bolli N, Biancon G, Moarii M, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32(12):1-29. https://doi.org/10.1038/leu.2017.344.
Yellapantula V, Hultcrantz M, Rustad EH, et al. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer J. 2019;9(12):101. https://doi.org/10.1038/s41408-019-0264-y.
White BS, Lanc I, O'Neal J, et al. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J. 2018;8(3):35. https://doi.org/10.1038/s41408-018-0062-y.
Perrot A, Lauwers-Cances V, Tournay E, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019;37(19):1657-1665. https://doi.org/10.1200/JCO.18.00776.
Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159-170. https://doi.org/10.1038/s41375-018-0196-8.
Frias S, Ramos S, Salas C, Molina B, Sánchez S, Rivera-Luna R. Nonclonal chromosome aberrations and genome chaos in somatic and germ cells from patients and survivors of Hodgkin lymphoma. Genes (Basel). 2019;10(1):37. https://doi.org/10.3390/genes10010037.